African-American Heart Failure Trial

A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.

The overall objective is confirmation of BiDil's Safety and Efficacy in African-American (AFA) Patients with Moderate to Severe Symptomatic Heart Failure.

• African American male or female 18 years or older.
• NYHA Class 3 & 4.
• Have either a resting LVEF less than or equal to 35% (by any method) or a resting LVIDD greater than 2.9 cm/m2 BSA (or greater than 6.5 cm) with LVEF less than 45% (by echocardiogram).